Was ist neu im 2022?

Infektiologie

Mirjam de Roche

PubMed.gov

malaria

Search

Advanced Create alert Create RSS User Guide

Save Email Send to Sorted by: Best match Display options

MY NCBI FILTERS

RESULTS BY YEAR



103,998 results

Page 1 of 10,400

1 **Malaria.**

Garcia LS.

Cite

Clin Lab Med. 2010 Mar;30(1):93-129. doi: 10.1016/j.cll.2009.10.001.

PMID: 20513543 Review.

Share

Approximately 90% of **malaria** deaths occur in Africa. Despite continuing efforts in vaccine development, **malaria** prevention is difficult, and no drug is universally effective. This article examines **malaria** caused by the 4 most common Plasmodium spp that infect ...

PubMed.gov

covid-19

Search

Advanced Create alert Create RSS User Guide

Save Email Send to Sorted by: Best match Display options

MY NCBI FILTERS

RESULTS BY YEAR

222,742 results

Page 1 of 22,275

Use COVID-19 filters from PubMed Clinical Queries to refine your search

Treatment Mechanism Transmission More filters

See more SARS-CoV-2 literature, sequence, and clinical content from NCBI

Evaluation of the Panbio **COVID-19** Rapid Antigen Detection Test Device for the

Neues in der Infektiologie

- Secondary attack rate
- Inkubationszeit
- Symptomspektrum
- Schweregrad der Erkrankung
- Dauer Virusauscheidung
- Re-Infektionsrate
- Diagnostik

Secondary attack rate

→ Anteil, die nach Kontakt an der Infektion erkrankt.

	Omicron				Delta				
Settings	Index cases	Close contacts	Second. Cases	SAR (CI 95)	Index cases	Close contacts	Second. Cases	SAR (CI 95)	Prop. difference (IC-95%)
Global	333	1126	443	**39.3%** (36.5 - 42.2)	1403	7013	1846	**26.3%** (25.3 - 27.4)	13* (9.9 - 16.1)
Unvaccinated index	210	655	269	**41.1%** (37.4 - 44.9)	535	2876	895	**31.1%**** (29.5 - 32.8)	10* (5.7 - 14.2)
Vaccinated index	111	436	159	**36.5%** (32.1 - 41.1)	829	3904	910	**23.3%**** (22 - 24.7)	13.2* (8.3 - 18)

Àguila-Mejia et al. Secondary Attack Rates, Transmission, Incubation and Serial Interval Periods of first SARS-CoV-2 Omicron variant cases in a northern region of Spain. Preprint. Research Square 2022

Inkubationszeit

	Mean (sd)				Median (q1, q3)	
	Ómicron	**Delta**	**Diff (IC 95%) ***	**p**	**Ómicron**	**Delta**
Incubation period	3.1 (2.6)	3.3 (2.7)	-0.2 (-0.6 - 0.16)	0.29	3 (1, 4)	3 (1, 5)
Unvaccinated index	3.1 (2.7)	3.3 (2.6)	-0.2 (-0.7 - 0.3)	0.46	3 (1, 4)	
Vaccinated index	3 (2.2)	3.4 (2.9)	-0.4 (-0.9 - 0.14)	0.16	3 (2, 4)	

Àguila-Mejia et al. Secondary Attack Rates, Transmission, Incubation and Serial Interval Periods of first SARS-CoV-2 Omicron variant cases in a northern region of Spain. Preprint. Research Square 2022

Symptome nach Variante

	Omicron	Delta	Vor-Delta
Schnupfen	oft	oft	manchmal
Kopfweh	oft	oft	oft
Müdigkeit	oft	oft	oft
Niesen	oft	manchmal	selten
Halsweh	oft	oft	manchmal
Husten	manchmal	oft	oft
Schüttelfrost	manchmal	manchmal	manchmal
Fieber	manchmal	manchmal	oft
Verlust Geruchssinn	selten	manchmal	oft
Atemnot	selten	manchmal	manchmal

Quelle: Zoe Study, UK, https://covid.joinzoe.com/us-2

Schweregrad der Erkrankung

	Omikron	Delta
Notfallkonsultation (pro 1000 Fälle)	87	92
Hospitalisation (pro 1000 Fälle)	27	68
Tod (pro 1000 Fälle)	9	16

Iuliano D et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022. MMWR Weekly Report 2022

Dauer Virussauscheidung



Hay J et al. 2022. "Viral dynamics and duration of PCRpositivity of the SARS-CoV-2 Omicron variant." Pre-print

Dauer Virussauscheidung



Japan National Institute of Infectious Diseases Disease Control and Prevention Center. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. https://www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.html

Reinfektionsrate

Table 3. Effectiveness of SARS-CoV-2 prior infection against reinfection with Alpha, Beta Delta, or Omicron variant.

	Cases (PCR-positive)		Controls (PCR-negative)		Effectiveness in % (95% CI)[‡]
	Prior infection	No prior infection	Prior infection	No prior infection	
Effectiveness against symptomatic infection					
A) Main analysis[*]					
Alpha	2	334	94	1,548	90.2 (60.2 to 97.6)
Beta	15	1,321	450	6,084	84.8 (74.5 to 91.0)
Delta	23	2,153	1,154	8,782	92.0 (87.9 to 94.7)
Omicron	412	5,284	1,620	9,053	56.0 (50.6 to 60.9)
B) Adjusting for vaccination status in conditional logistic regression[‡]					
Alpha	2	334	94	1,548	90.3 (60.4 to 97.6)
Beta	15	1,321	450	6,084	84.0 (73.1 to 90.5)
Delta	23	2,153	1,154	8,782	91.9 (87.8 to 94.7)
Omicron	412	5,284	1,620	9,053	55.9 (50.5 to 60.8)
C) Excluding vaccinated individuals[†]					
Alpha	1	285	94	1,294	95.3 (66.0 to 99.3)
Beta	11	1,084	312	4,976	83.9 (70.4 to 91.2)
Delta	11	1,026	400	3,966	90.5 (81.9 to 94.6)
Omicron	60	1,031	258	1,738	61.9 (48.2 to 72.0)
Effectiveness against severe, critical, or fatal COVID-19[§]					
Alpha	1	44	15	199	69.4 (-143.6 to 96.2)
Beta	2	186	76	824	88.0 (50.7 to 97.1)
Delta	0	135	56	528	100 (43.3 to 99.8)[¶]
Omicron	2	70	39	167	87.8 (47.5 to 97.1)

Altarawneh H et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. medRxiv 2022.01.05.22268782; doi: https://doi.org/10.1101/2022.01.05.22268782

Zuverlässigkeit Antigentests



Schrom et al. Direct Comparison of SARS-CoV-2 Nasal RT-PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge. Medrix 2022. https://doi.org/10.1101/2022.01.08.22268954

Zuverlässigkeit Antigentests



Schrom et al. Direct Comparison of SARS-CoV-2 Nasal RT-PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge. Medrix 2022.